Literature DB >> 30353857

Stretching the boundaries for liver transplant in the 21st century.

María Trapero-Marugán1, Ester Coelho Little2, Marina Berenguer3.   

Abstract

Given the high waiting list mortality, there is a clear need to identify strategies to increase the number of livers for transplantation. Some strategies require policy changes, whereas others depend on a better understanding of available opportunities. We divided the strategies to increase the number of livers for transplantation into two categories-those aiming to increase the use of organs considered to be of suboptimal quality, and those aiming to increase the use of organs considered to be of suboptimal size. Enough evidence suggests that, if considered in the context of other donor and recipient variables, grafts from elderly donors are a safe option. The severity of steatosis, and not simply its presence, is an important factor in contemplating the utility of steatotic grafts. Use of organs that have steatosis together with other factors that define extended-criteria organs should be avoided, particularly prolonged cold ischaemia time. Donation after circulatory death has an important role in increasing the donor pool, given the wide availability of organs from donors with this cause of death. This type of donation is hampered by a higher risk of ischaemia-reperfusion injury than other types of donation, which can result in graft complications and potential graft loss. Different types of machine perfusion have the potential to overcome these issues, and further research is needed to establish the best techniques and most cost-effective models. Despite the scarcity of data, the availability of safe and highly effective antiviral therapies means that the use of donors infected with hepatitis C virus (HCV) in recipients who are HCV negative can be considered as a strategy to increase the donor pool. Although data on transplantations using livers from living donors in patients with a Model for End-Stage Liver Disease (MELD) score higher than 20-24 are scarce, outcomes are similar to those achieved in patients with lower MELD scores, at least in reference centres. Increased use of split livers is an option if donors and recipients are carefully selected.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30353857     DOI: 10.1016/S2468-1253(18)30213-9

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  5 in total

1.  Heme oxygenase-1-modified bone marrow mesenchymal stem cells combined with normothermic machine perfusion to protect donation after circulatory death liver grafts.

Authors:  Huan Cao; Liu Yang; Bin Hou; Dong Sun; Ling Lin; Hong-Li Song; Zhong-Yang Shen
Journal:  Stem Cell Res Ther       Date:  2020-06-05       Impact factor: 6.832

2.  Macrophage Membrane-Coated Nanoparticles Alleviate Hepatic Ischemia-Reperfusion Injury Caused by Orthotopic Liver Transplantation by Neutralizing Endotoxin.

Authors:  Zhibing Ou; Hua Zhong; Liang Zhang; Minghua Deng; Wenfeng Zhang; Jingyuan Wang; Huaguo Feng; Jianping Gong; Chunmu Miao; Zhujun Yi
Journal:  Int J Nanomedicine       Date:  2020-06-11

Review 3.  Organ donation and transplantation: a multi-stakeholder call to action.

Authors:  Raymond Vanholder; Beatriz Domínguez-Gil; Mirela Busic; Helena Cortez-Pinto; Jonathan C Craig; Kitty J Jager; Beatriz Mahillo; Vianda S Stel; Maria O Valentin; Carmine Zoccali; Gabriel C Oniscu
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

4.  Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.

Authors:  Naroa Goikoetxea-Usandizaga; Marina Serrano-Maciá; Teresa C Delgado; Jorge Simón; David Fernández Ramos; Diego Barriales; Maria E Cornide; Mónica Jiménez; Marina Pérez-Redondo; Sofia Lachiondo-Ortega; Rubén Rodríguez-Agudo; Maider Bizkarguenaga; Juan Diego Zalamea; Samuel T Pasco; Daniel Caballero-Díaz; Benedetta Alfano; Miren Bravo; Irene González-Recio; Maria Mercado-Gómez; Clàudia Gil-Pitarch; Jon Mabe; Jordi Gracia-Sancho; Leticia Abecia; Óscar Lorenzo; Paloma Martín-Sanz; Nicola G A Abrescia; Guadalupe Sabio; Mercedes Rincón; Juan Anguita; Eduardo Miñambres; César Martín; Marina Berenguer; Isabel Fabregat; Marta Casado; Carmen Peralta; Marta Varela-Rey; María Luz Martínez-Chantar
Journal:  Hepatology       Date:  2021-12-15       Impact factor: 17.298

Review 5.  Obesity in the Liver Transplant Setting.

Authors:  Carlos Moctezuma-Velazquez; Ernesto Márquez-Guillén; Aldo Torre
Journal:  Nutrients       Date:  2019-10-23       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.